2008•NeuroendocrinologyRequires access

A VI Vasopressin Receptor Antagonist Has Nonspecific Neurodepressant Actions in the Spinal Cord

James Paul Porter, Michael J. Brody

Open publisher page 14 citations

Abstract

In the present investigation, we injected d(CH2)5Tyr(Me)AVP, a specific VI vasopressin antagonist, into the intrathecal space of the spinal cord to determine whether spinal vasopressin-containing neurons contribute to the hemodynamic effects produced by stimulation of the paraventricular nucleus (PVN). The intrathecal antagonist reduced the cardiovascular effects of PVN stimulation, but also reduced the effects produced by stimulating 2 other brain sites which do not contain vasopressin cell bodies. In addition, intrathecal administration of the vasopressin antagonist had a similar effect in Brattleboro rats which do not produce vasopressin. In conscious rats with indwelling intrathecal catheters, the vasopressin antagonist produced reversible hindlimb paralysis. These data suggest that d(CH2)5Tyr(Me)AVP has nonspecific actions within the spinal cord not related to the blockade of vasopressin receptors.

About this research paper

What this paper is about

In the present investigation, we injected d(CH2)5Tyr(Me)AVP, a specific VI vasopressin antagonist, into the intrathecal space of the spinal cord to determine whether spinal vasopressin-containing neurons contribute to the hemodynamic effects produced by stimulation of the paraventricular nucleus (PVN). The intrathecal antagonist reduced the cardiovascular effects of PVN stimulation, but also reduced the effects produced by stimulating 2 other brain sites which do not contain vasopressin cell bodies. In addition, intrathecal administration of the vasopressin antagonist had a similar effect in Brattleboro rats which do not produce vasopressin. In conscious rats with indwelling intrathecal catheters, the vasopressin antagonist produced reversible hindlimb paralysis. These data suggest that d(CH2)5Tyr(Me)AVP has nonspecific actions within the spinal cord not related to the blockade of vasopressin receptors.

Why it matters

OpenAlex reports 14 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

In the present investigation, we injected d(CH2)5Tyr(Me)AVP, a specific VI vasopressin antagonist, into the intrathecal space of the spinal cord to determine whether spinal vasopressin-containing neurons contribute to the hemodynamic effects produced by stimulation of the paraventricular nucleus (PVN). The intrathecal antagonist reduced the cardiovascular effects of PVN stimulation, but also reduced the effects produced by stimulating 2 other brain sites which do not contain vasopressin cell bodies. In addition, intrathecal administration of the vasopressin antagonist had a similar effect in Brattleboro rats which do not produce vasopressin. In conscious rats with indwelling intrathecal catheters, the vasopressin antagonist produced reversible hindlimb paralysis. These data suggest that d(CH2)5Tyr(Me)AVP has nonspecific actions within the spinal cord not related to the blockade of vasopressin receptors.

Key concepts: Vasopressin, Vasopressin receptor, Spinal cord, Endocrinology, Antagonist, Internal medicine, Receptor antagonist, Medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
A VI Vasopressin Receptor Antagonist Has Nonspecific Neurodepressant Actions in the Spinal Cord — Research Paper | ScholarLens